Thyroid dysfunctions due to immune checkpoint inhibitors: A review

dc.contributor.authorSabbagh, Rawaa El
dc.contributor.authorAzar, Nadim S.
dc.contributor.authorEid, Assaad A.
dc.contributor.authorAzar, Sami T.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentAnatomy, Cell Biology, and Physiological Sciences
dc.contributor.departmentDivision of Endocrinology and Metabolism
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:59:46Z
dc.date.available2025-01-24T11:59:46Z
dc.date.issued2020
dc.description.abstractAim: Immune checkpoint inhibitors are anti-cancer drugs associated with adverse events that result from releasing the immune system against self-antigens while attacking cancer cells. Thyroid dysfunctions are among the most common associated adverse events. Materials and Methods: We conducted a systematic search of the literature in 2 databases: PubMed and Medline. Articles that reported thyroid adverse events of immune checkpoint inhibitors were reviewed. Thyroid disorders include hyperthyroidism and hypothyroidism and are most commonly seen with programmed cell death protein 1 and programmed death-ligand 1 inhibitors. Conclusions: Thyroid disorders are common side effects seen with check point inhibitors and are treated, depending on the clinical situation, by adequate hormonal replacement, thionamides, corticosteroids or observation only. The use of high dose corticosteroids has not been established as a treatment of thyroid toxicities. Thyroid function tests screening should be a part of baseline laboratory testing of all patients undergoing treatment with immune checkpoint inhibitors. © 2020, Dove Medical Press Ltd. All rights reserved.
dc.identifier.doihttps://doi.org/10.2147/IJGM.S261433
dc.identifier.eid2-s2.0-85096211302
dc.identifier.urihttp://hdl.handle.net/10938/31387
dc.language.isoen
dc.publisherDove Medical Press Ltd
dc.relation.ispartofInternational Journal of General Medicine
dc.sourceScopus
dc.subjectAnti-pd1
dc.subjectAnti-pdl1
dc.subjectImmune check point inhibitors
dc.subjectThyroid dysfunction
dc.subjectAtezolizumab
dc.subjectAvelumab
dc.subjectCemiplimab
dc.subjectCorticosteroid
dc.subjectCytotoxic t lymphocyte antigen 4
dc.subjectDurvalumab
dc.subjectImmune checkpoint inhibitor
dc.subjectLevothyroxine
dc.subjectNivolumab
dc.subjectPembrolizumab
dc.subjectProgrammed death 1 ligand 1
dc.subjectProgrammed death 1 receptor
dc.subjectThionamide
dc.subjectClinical feature
dc.subjectClinical observation
dc.subjectDisease association
dc.subjectDrug classification
dc.subjectDrug indication
dc.subjectDrug overdose
dc.subjectHormone substitution
dc.subjectHuman
dc.subjectHyperthyroidism
dc.subjectHypothyroidism
dc.subjectIncidence
dc.subjectMyxedema
dc.subjectPathogenesis
dc.subjectPatient care
dc.subjectPractice guideline
dc.subjectReview
dc.subjectScreening
dc.subjectSystematic review
dc.subjectThyroid disease
dc.subjectThyroiditis
dc.subjectThyrotoxicosis
dc.titleThyroid dysfunctions due to immune checkpoint inhibitors: A review
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2020-7038.pdf
Size:
1.1 MB
Format:
Adobe Portable Document Format